In conclusion, our findings demonstrate that IRF4 expressed in skeletal muscle plays a critical role in the pathogenesis of NASH through the FSTL1-DIP2A/CD14 pathway. The gene discussed is FSTL1; the disease is metabolic dysfunction-associated steatohepatitis.